|
|
|
|
|
|
|
|
|
14.07.26 - 04:48
|
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus (RTTNews)
|
|
|
Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder Innovations, which recently raised its full-year revenue guidance, among others....
|
|
|
13.07.26 - 16:48
|
MGM Rises on Takeover Bid; SK Hynix Falls on Memory Pullback | Stock Movers (Bloomberg)
|
|
|
On this episode of Stock Movers:
- MGM Resorts International (MGM) shares are rising on a report regarding a potential takeover bid from Barry Diller.
- SK Hynix (SKHY) shares are lower and other memory stocks are also falling. It is lower over concerns with the sustainability of artificial-intelligence spending. The drop in South Korean trading is likely to cause a hit to the American depositary receipts as well. The debate between the optimists and pessimists will continue, which should create volatility, according to Hendi Susanto, portfolio manager at Gabelli Funds.
- Agenus (AGEN) shares are moving higher on news of a deal that it's selling up to $3540 million worth of securities. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
13.07.26 - 12:06
|
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer (Business Wire)
|
|
|
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer
Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise
ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3
To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer
Company to host conference call and webcast today at 8:30 a.m. ET
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOT--Agenus Inc....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.05.26 - 14:48
|
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development (Business Wire)
|
|
|
Authorized access interest continues to expand across regions
Phase 3 BATTMAN trial commenced patient enrollment in April 2026, advancing BOT+BAL into pivotal evaluation
Zydus collaboration closed in January, delivering strategic capital, strengthening Agenus' balance sheet and securing dedicated U.S. biologics manufacturing capacity
Agenus continues to align operating priorities around BOT+BAL, financial discipline and commercial readiness
SEC concluded its investigation in May 2026 with no enforcement action recommended; Related putative securities class action dismissed in its entirety by the U.S. District Court for the District of Massachusetts in March 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BATTMAN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, and provided an operational update on botensilimab plus balstilimab (BOT+BAL), the Company's lead clinical program and one of the most clinically advan...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
